why choose us

First received: July 21, 2022

Clinical Trial: A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumors

Study Type: INTERVENTIONAL


Official Title: Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

Brief Summary: This study is open to adults with different types of advanced cancer.People can take part if previous treatment was not successful, or no treatment exists.The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab.BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer.In this study, BI 1703880 is given to people for the first time.Participants get BI 1703880 and ezabenlimab…

Read more